Abstract | BACKGROUND: PATIENTS AND METHODS: Records of advanced NSCLC patients who received erlotinib from 2007 to 2012 at a large, centralized, cancer institution were retrospectively reviewed. Pertinent demographic data were collected and concomitant AS treatment was defined as AS prescription dates overlapping with ≥ 20% of erlotinib treatment duration. Records of patients who received erlotinib for ≥ 1 week were analyzed for progression-free survival (PFS) and overall survival (OS). RESULTS: Stage IIIB/IV NSCLC patients (n = 544) were identified and 507 had adequate data for review. The median age was 64 years and 272 were female. Adenocarcinoma (n = 318; 64%) and squamous (n = 106; 21%) were predominant subtypes; 124 patients received concomitant AS therapy. In this unselected population, median PFS and OS in AS versus no AS groups were 1.4 versus 2.3 months (P < .001) and 12.9 versus 16.8 months (P = .003), respectively. Factoring sex, subtype, and performance status in multivariate Cox proportional hazards ratios for PFS and OS between AS and no AS groups were 1.83 (95% confidence interval [CI], 1.48-2.25) and 1.37 (95% CI, 1.11-1.69), respectively. CONCLUSION: This large population-based study suggests erlotinib efficacy might be linked with gastric pH and OS could be adversely affected. To our knowledge, this is the first study demonstrating a possible negative clinical effect of coadministration of erlotinib with AS therapy. Further prospective investigation is warranted.
|
Authors | Michael P Chu, Sunita Ghosh, Carole R Chambers, Naveen Basappa, Charles A Butts, Quincy Chu, David Fenton, Anil A Joy, Randeep Sangha, Michael Smylie, Michael B Sawyer |
Journal | Clinical lung cancer
(Clin Lung Cancer)
Vol. 16
Issue 1
Pg. 33-9
(Jan 2015)
ISSN: 1938-0690 [Electronic] United States |
PMID | 25246385
(Publication Type: Journal Article)
|
Copyright | Copyright © 2015 Elsevier Inc. All rights reserved. |
Chemical References |
- Histamine H2 Antagonists
- Protein Kinase Inhibitors
- Quinazolines
- Erlotinib Hydrochloride
- Omeprazole
|
Topics |
- Carcinoma, Non-Small-Cell Lung
(complications, drug therapy, mortality)
- Drug Interactions
- Erlotinib Hydrochloride
- Female
- Gastric Acid
(metabolism)
- Gastroesophageal Reflux
(complications, drug therapy, mortality)
- Histamine H2 Antagonists
(administration & dosage, adverse effects)
- Humans
- Lung Neoplasms
(complications, drug therapy, mortality)
- Male
- Middle Aged
- Omeprazole
(administration & dosage, adverse effects)
- Population Groups
- Protein Kinase Inhibitors
(administration & dosage, adverse effects)
- Quinazolines
(administration & dosage, adverse effects)
- Retrospective Studies
- Survival Analysis
- Treatment Outcome
|